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Motoi Aoe, MD,* Yoshifumi Sano, MD,* and Hiroshi Date, MD*
Background: The purpose of this study was to identify risk factors
for disease recurrence and unfavorable prognosis after surgical
resection for stage I non-small cell lung cancer in patients with
tumor diameters of 20 mm.
Methods: One hundred sixty-three patients who had pathologic
stage I non-small cell lung cancer with tumor diameters 20 mm
and who had undergone a lobectomy with mediastinal lymph node
dissection were retrospectively reviewed. The relationships between
clinicopathologic factors and clinical outcomes, including recur-
rence and survival, were then examined. The clinicopathologic
factors examined in this study were age, sex, smoking status,
preoperative serum carcinoembryonic antigen level, pathologic tu-
mor size, histologic subtype, histologic grade, and visceral pleural
invasion.
Results: Among the clinicopathologic factors that were examined,
the histologic grade of the carcinoma status was significantly related
to a high risk of recurrence when analyzed using univariate (p 
0.01) and multivariate analyses (p  0.049). Regarding survival,
patients with poorly differentiated carcinomas showed a signifi-
cantly unfavorable overall survival (p  0.001), disease-specific
survival (p  0.003), and disease-free survival (p  0.002) com-
pared with patients with well-/moderately differentiated carcinomas
according to univariate analyses. A Cox proportional hazards model
indicated that a poorly differentiated carcinoma status was the only
independent factor for an unfavorable overall survival (p  0.02),
disease-specific survival (p 0.046), and disease-free survival (p 
0.04).
Conclusions: Poor differentiation of tumor was the only risk factor
for recurrence and an unfavorable prognosis for stage I non-small
cell lung cancer patients with tumor diameters of 20 mm.
KeyWords: Non-small cell lung cancer, Stage I, Tumor diameter of
20 mm, Prognostic factor, Histologic grade.
(J Thorac Oncol. 2007;2: 808–812)
Lung cancer is the leading cause of cancer death in Japanand many countries around the world.1,2 Survival among
patients with non-small cell lung cancer (NSCLC) remains
unsatisfactory because many locally advanced or metastatic
cases are unresectable.3 Even patients with early stages of the
disease who undergo complete resections often experience
recurrences, resulting in an unfavorable prognosis.
Recently, the detection rate of small peripheral lung
cancer has been increasing as a result of advances in diag-
nostic technology, including high-resolution computed to-
mography.4 Unfortunately, approximately 30% of patients
with stage IA NSCLC die within 5 years of surgery.5,6 Recent
studies have demonstrated the usefulness of postoperative
adjuvant chemotherapy among patients with stage IB to IIIA
NSCLC who have undergone complete resections.7–9 These
facts suggest that adjuvant chemotherapy for high-risk pa-
tients with stage IA NSCLC may be useful for improving
survival in this population. Kato et al.10 reported that adjuvant
chemotherapy with uracil-tegafur prolonged survival among
patients with stage I adenocarcinoma and a tumor diameter of
20 mm. They concluded that patients with tumor diameters of
20 mm should be excluded from adjuvant therapy unless a
subgroup with a poor prognosis was identified. This consider-
ation encouraged us to identify factors associated with recur-
rence and a poor prognosis as indicators for adjuvant chemo-
therapy among patients with tumor diameters 20 mm.
In this study, we retrospectively analyzed the relation-
ship between clinicopathologic factors and the clinical
courses of patients with stage I NSCLC and tumor diameters
20 mm to identify risk factors for recurrence and unfavor-
able prognosis after surgery.
METHODS
Between January 1995 and December 2002, 734 con-
secutive patients with NSCLC underwent pulmonary resec-
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tions at the Department of Cancer and Thoracic Surgery,
Okayama University Hospital. Among them, 163 patients
who had pathologic stage I disease with a tumor diameter of
20 mm and who had undergone a lobectomy with medias-
tinal lymph node dissection as a part of complete resection
were included in the current study. The primary treatment in
this group was pulmonary resection without chemotherapy or
radiotherapy before surgery. The following clinicopathologic
factors were evaluated: age, sex, smoking status, preoperative
serum carcinoembryonic antigen (CEA) level, pathologic
tumor size, histologic subtype, histologic grade, and visceral
pleural invasion. The cutoff CEA level was set at 5.0 ng/ml
between the normal and elevated groups. The histologic
grade was categorized into well-differentiated, moderately
differentiated, and poorly differentiated carcinoma according
to the degree of structural and cytologic atypia. Differentia-
tion in squamous cell carcinoma was determined based on
degree of keratinization, intercellular bridges, and squamous
pearl formation. Poor differentiation in squamous cell carci-
noma was defined as a solid pattern tumor with little degree
of these features (5%). Adenocarcinoma basically com-
posed of malignant glandular epithelium was evaluated by
replacing alveolar walls and tubular and papillary structure.
Poor differentiation in adenocarcinoma was defined as a solid
pattern tumor without any clear gland formation. Clinicopath-
ologic staging was determined according to the International
Union Against Cancer’s tumor-node-metastasis classification
of malignant tumors.11 Pleural involvement was classified
according to the rules of the Japan Lung Cancer Society12: (1)
a tumor of any size that was exposed on the visceral pleural
surface was categorized as p2 and was classified as a patho-
logic T2 tumor and (2) a tumor that extends beyond the
elastic layer of the visceral pleura but is not exposed on the
pleural surface was categorized as p1 and was classified as
T1. Thus, although we had three patients with p1 disease, all
patients in this study were classified as stage IA based on
rules of Japan Lung Cancer Society.
TABLE 1. Relationship Between Recurrence and
Clinicopathologic Factors in Patients With Stage I NSCLC
Tumors 20 mm in Diameter
Variables and Subsets Recurrences, n (%) p
Age, yr (n)
65 (94) 10 (10.6) 0.40
65 (69) 4 (5.8)
Sex (n)
Male (89) 9 (10.1) 0.58
Female (74) 5 (6.8)
Smoking history (n)
Ever smoker (85) 10 (11.8) 0.26
Never smoker (78) 4 (5.1)
Serum CEA level, ng/mla (n)
5.0 (20) 4 (20.0) 0.11
5.0 (140) 10 (7.1)
Pathologic tumor size, mm (n)
15 (71) 6 (8.5) 1.00
15 (92) 8 (8.7)
Histologic gradeb (n)
Well/moderately (156) 9 (5.8) 0.01
Poorly (16) 5 (31.3)
Histologic subtype (n)
Adeno (136) 13 (9.6) 0.70
Nonadeno (27) 1 (3.7)
Visceral pleural invasion (n)
p0 (160) 13 (8.1) 0.28
p1c (3) 1 (33.3)
Adeno, adenocarcinoma; CEA, carcinoembryonic antigen; Nonadeno, nonadeno-
carcinoma; NSCLC, non-small cell lung cancer.
a The serum CEA level was not evaluated in three patients.
b Histologic grade was not determined in one adenosquamous carcinoma.
c Visceral pleural involvement was classified according to the rules of the Japan
Lung Cancer Society: p1, tumor that extends beyond the elastic layer of the visceral
pleura but is not exposed on the pleural surface.
















1 59 Male Current 4.46 13 Ad Poor p1 Liver
2 68 Male Current 5.88 9 Ad Poor p0 Lung, meningitis
3 71 Female Former 15.23 18 Ad Poor p0 Neck LN
4 72 Male Current 3.98 20 Sq Poor p0 Liver
5 76 Male Former 18.22 14 Ad Poor p0 Mediastinal LN, pericardium
6 47 Female Never 1.22 14 Ad Moderate p0 Malignant pleural effusion
7 56 Male Former 1.68 20 Ad Moderate p0 Lung, bone, mediastinal LN
8 69 Male Current 6.10 16 Ad Moderate p0 Lung
9 70 Male Former 1.36 15 Ad Moderate p0 Lung
10 71 Male Former 2.12 20 Ad Moderate p0 Brain, small intestine, neck LN
11 57 Female Never 0.79 20 Ad Well p0 Lung, malignant pleural effusion
12 65 Female Never 1.14 15 Ad Well p0 Lung, brain
13 73 Female Never 1.70 15 Ad Well p0 Brain
14 75 Male Former 2.87 13 Ad Well p0 Lung
Ad, adenocarcinoma; LN, lymph node; Sq, squamous cell carcinoma.
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Patients were followed at the outpatient clinic at least
every 6 months for 2 years after surgery and annually there-
after. All patients underwent a complete blood count, blood
chemistry analysis, plain chest radiograph, measurement of
serum CEA level, and a computed tomography scan of the
chest and abdomen to screen for recurrent disease when
appropriate. Biopsies of new lesions suspected to be recur-
rences were performed, if possible, and the attending physi-
cian made the final diagnosis regarding relapse. The overall
survival (OS) and the disease-free survival (DFS) periods
were calculated from the date of surgery until the date of
death or the last follow-up for OS and the date of recurrence
or the last follow-up for DFS. The disease-specific survival
period was also calculated from the date of surgery until the
date of original disease-related death or the last follow-up;
patients who died from other causes were considered cen-
sored cases.
Differences in significance among categorized groups
were compared using Fisher’s exact or 2 tests, as appropriate.
Univariate analyses of survival were performed using the
Kaplan-Meier method and a log-rank test. Multivariate analyses
for recurrence were performed using a multilogistic regression
model. Multivariate analyses for survival were performed using
a Cox proportional hazards model. All data were analyzed using
StatView 5.0 Program for Windows (SAS Institute Inc., Cary,
NC). All statistical tests were two sided, and probability values
0.05 were regarded as statistically significant.
RESULTS
Details of the patient characteristics are shown in Table
1. The median age was 64 years (range, 30–84 years); 89
male and 74 female patients were examined retrospectively.
One hundred thirty-six patients (83.4%) had adenocarcinoma
histology, 26 (16.0%) had squamous cell carcinoma histol-
ogy, and one (0.6%) had adenosquamous carcinoma histol-
ogy. The histologic grade was determined as well differenti-
ated in 86 (52.8%) cases, moderately differentiated in 60
(36.8%) cases, and poorly differentiated in 16 (9.8%) cases.
The histologic grade was not determined in one adenosqua-
mous carcinoma. Because the Kaplan-Meier survival curves
for patients with well-differentiated and moderately differen-
tiated carcinomas were similar, we considered well-differen-
tiated and moderately differentiated carcinomas as one group
(supplemental material).
FIGURE 1. Crude survival curves stratified according to histologic grade. (A) Overall survival. (B) Disease-specific survival. (C)
Disease-free survival.
TABLE 3. Multivariate Analysis for Recurrence
Variable Odds Ratio 95% CI p
Age 1.93 0.13–2.03 0.35
Sex 2.33 0.053–3.49 0.43
Smoking status 4.02 0.45–36.31 0.22
Serum CEA level 1.23 0.22–6.77 0.82
Pathologic tumor size 0.90 0.26–3.08 0.87
Histologic subtype 0.26 0.028–2.34 0.23
Histologic grade 4.94 1.01–24.21 0.049
Visceral pleural invasion 4.89 0.28–84.57 0.28
CEA, carcinoembryonic antigen; CI, confidence interval.
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Of the total study population, the 5-year OS, disease-
specific survival, and DFS rates were 91.4%, 93.3%, and
91.4%, respectively. Fourteen patients (8.4%) developed re-
currences after surgical resection. Detailed data regarding the
recurrences are shown in Table 2. No local recurrences at the
bronchial stump were reported. According to univariate anal-
yses, a poorly differentiated carcinoma status was the only
risk factor significantly associated with recurrence (p 
0.01). No significant differences in disease recurrence accord-
ing to age, sex, smoking status, serum CEA level, pathologic
tumor size, histologic subtype, or visceral pleural invasion
were observed (Table 1). A multivariate analysis indicated
that histologic grade was the only independent factor associ-
ated with disease recurrence (odds ratio  4.94, 95% confi-
dence interval [CI]: 1.01–24.21, p  0.049) (Table 3). With
regard to survival, univariate analyses indicated that ad-
vanced age (65 years and older) (p  0.005), male sex (p 
0.01), ever smoking status (p  0.005), high CEA level (5)
(p  0.005), and poor differentiation of the tumor (p 
0.001) were significantly related to the poor OS. In addition,
patients with poorly differentiated carcinomas also showed a
significantly poor disease-specific survival (p  0.003) and
DFS (p 0.002), compared with those with well-/moderately
differentiated carcinomas (Figure 1). A Cox proportional
hazards analysis indicated that poorly differentiated carci-
noma was the only independent factor associated with an
unfavorable OS (hazard ratio 3.61, 95% CI: 1.24–10.51, p
0.02), disease-specific survival (hazard ratio  4.20, 95% CI:
1.03–17.12, p  0.046), and DFS (hazard ratio  4.45, 95%
CI: 1.09–18.19, p  0.04) (Table 4).
DISCUSSION
Recent randomized phase III trials have shown that
patients with stage IB–IIIA NSCLCs are candidates for ad-
juvant chemotherapy after complete surgical resection.7–9 The
indications for adjuvant chemotherapy among patients with
stage IA NSCLC, conversely, are still under debate, despite the
performance of subset analyses in randomized trials. One reason
for the debate is the small NSCLCs, especially adenocarcinomas
with a dominant bronchoalveolar carcinomatous component, are
unlikely to recur after surgery.13 Thus, the natural prognosis of
this population may already be good enough that any additional
benefits from adjuvant chemotherapy would prove to be mini-
mal, without further selection to identify a subpopulation with a
poor natural prognosis.
Previous studies have reported several factors associ-
ated with a poor prognosis in patients with small NSCLCs:
tumor size, preoperative serum CEA level, visceral pleural
invasion, vascular vessel invasion, and histologic grade.14–18
We focused on the risk factor for recurrence as well as
unfavorable survival time in this study to identify candidates
for adjuvant chemotherapy. A recent large-scale study also
indicated that patients with less differentiated carcinomas
after resection had a higher risk of recurrence and death,
according to a multivariate analysis. Ichinose et al.14 also
reported that histologic grade was a significant predictor of a
poor prognosis for patients with resected stage I tumors.
In this study, the subjects were limited to patients with
stage I NSCLC tumors with diameters 20 mm. Our main
result was that poor tumor differentiation was the only inde-
pendent risk factor for recurrence and an unfavorable prog-
nosis. Histologic grade classifications are assumed to lack
objectivity because no specific criteria have been developed
for standardizing lung cancer histology. Although a four-
tiered system of grading (well-differentiated, moderately dif-
ferentiated, poorly differentiated, and undifferentiated carci-
nomas) for lung cancer is mentioned in the World Health
Organization’s Histological Typing of Lung and Pleural Tu-
mors,19 histologic grade was removed from the current crite-
ria of the Japan Lung Cancer Society.12 However, our result
indicates that poor tumor differentiation has a crucial contri-
bution to poor clinical outcome, suggesting that this factor
may be a useful indicator of a need for postoperative adjuvant
chemotherapy in patients with small NSCLC. Thus, an ob-
jective grading system should be developed, not only for
enabling reproducible assessments, but also for determining
treatment strategies in patients with NSCLC.
It should be noted that our cohort mainly consisted of
adenocarcinoma accounting for 83.4%. Thus, our results
mainly reflected the feature of adenocarcinomas despite his-
tologic subtype was adjusted by multivariate analysis. Further
TABLE 4. Multivariate Analysis for Survival
Variables Hazard Ratio 95% CI p
A. Overall survival
Age 3.57 0.078–1.01 0.051
Sex 1.27 0.14–11.60 0.83
Smoking status 2.18 0.23–20.64 0.50
Serum CEA level 1.03 0.34–3.08 0.97
Pathologic tumor size 1.67 0.68–4.12 0.26
Histologic subtype 1.06 0.39–2.91 0.90
Histologic grade 3.61 1.24–10.51 0.02
Visceral pleural invasion 4.15 0.49–35.35 0.19
B. Disease-specific survival
Age 1.71 0.17–2.06 0.40
Sex 2.65 0.063–2.27 0.29
Smoking status 4.20 0.59–30.01 0.15
Serum CEA level 1.23 0.27–5.55 0.79
Pathologic tumor size 1.12 0.35–3.54 0.85
Histologic subtype 0.33 0.040–2.75 0.31
Histologic grade 4.20 1.03–17.12 0.046
Visceral pleural invasion 3.91 0.44–34.83 0.22
C. Disease-free survival
Age 1.74 0.16–2.02 0.39
Sex 2.51 0.067–2.37 0.31
Smoking status 4.12 0.58–29.31 0.16
Serum CEA level 1.15 0.25–5.25 0.85
Pathologic tumor size 0.98 0.32–3.04 0.98
Histologic subtype 0.36 0.043–2.94 0.34
Histologic grade 4.45 1.09–18.19 0.04
Visceral pleural invasion 5.20 0.58–46.49 0.14
CEA, carcinoembryonic antigen; CI, confidence interval.
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study was warranted to identify factors for poor clinical
outcome focusing on nonadenocarcinoma histology.
In conclusion, we showed that a poor differentiation of
tumor was the only risk factor for recurrence and an unfavorable
prognosis in patients with stage I NSCLC and a tumor diameter
of20mm. A histologic grade may be an indicator of a need for
postoperative adjuvant chemotherapy to improve the clinical
outcome of patients with stage I NSCLC and a tumor size
20 mm. Randomized trials of adjuvant chemotherapy target-
ing poorly differentiated small NSCLC are warranted to confirm
our retrospective findings and to establish an appropriate thera-
peutic strategy for NSCLC patients with small tumors.
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FIGURE 2. Crude survival curves stratified according to well, moderately, and poorly differentiated histologic grade. (A)
Overall survival. (B) Disease-specific survival. (C) Disease-free survival.
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